MTOR and renal cell carcinoma: However, current treatments for RCC, including anti-angiogenic drugs, mTOR inhibitors, and immunotherapy combinations, can only extend the lives of many patients but rarely achieve complete remission, as almost all tumors progress within 2 years (10, 11).